Drug Profile


Alternative Names: Dexilant; Dexivant; Kapidex™; T 168390; TAK-390; TAK-390 modified release; TAK-390MR; TAK-390MROD

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Erosive oesophagitis; Gastro-oesophageal reflux
  • Phase I Gastrointestinal disorders

Most Recent Events

  • 17 Aug 2017 Dexlansoprazole market licensed to Hikma Pharmaceuticals in Middle East and North Africa, excluding Saudi Arabia, United Arab Emirates and Egypt
  • 14 Jul 2017 Takeda completes a phase I trial in Healthy volunteers in USA (PO) (NCT03131895)
  • 24 Apr 2017 Takeda initiates a phase I trial in Healthy volunteers in USA (PO) (NCT03131895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top